番茄社区

Charles Bankhead

Charles Bankhead

Authors >

Charles Bankhead

Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. His career spans more than 30 years, including a decade with Medical World News, a leading medical trade magazine of its time. He had a long and successful freelance career before joining 番茄社区 in 2007. Charles graduated with honors from Texas Tech University, receiving a BA in journalism, and completed a master's degree in mass communication, with specialization in health communication, also at Texas Tech.

Connect:

email image

Latest from Charles Bankhead

FDA Panel Puts Brakes on Anti-PARP Drug

WASHINGTON -- Approval of a PARP inhibitor for patients with advanced ovarian cancer should await results of an ongoing clinical trial that has the potential to answer questions about the drug's safety and efficacy, according to an FDA advisory committee that voted against immediate approval.

ASCO: Myeloma Study Results Inconclusive

CHICAGO -- A trial comparing two immunomodulatory regimens for myeloma failed to demonstrate noninferiority for the newer drug.

ASCO: Combo Extends PFS in Relapsed Myeloma

CHICAGO -- Progression-free survival in relapsed/refractory myeloma increased significantly in patients treated with a three-drug regimen that included panobinostat versus a two-drug regimen, a randomized trial showed.

ASCO: Targeted Combo Extends PFS in Ovarian Ca

CHICAGO -- Progression-free survival almost doubled in women with platinum-sensitive relapsed ovarian cancer treated with two targeted drugs instead of one, investigators reported here.

AUA Offers Guidance for Kidney Stones

ORLANDO -- Treatment tailored to individual patient and stone characteristics provides the basis for an American Urological Association clinical guideline on medical management of kidney stones.

Enzyme Tx Durable for Peyronie's

ORLANDO -- Three-fourths of men with moderate to severe Peyronie's disease had meaningful improvement a year after treatment with an enzyme that dissolves scar tissue, investigators reported here.

FDA Warns of Cancer Risk With Laparoscopic Device

WASHINGTON -- Hysterectomy and procedures to remove uterine fibroids should avoid use of laparoscopic power morcellation, according to a safety advisory from the Food and Drug Administration.

Cologuard Cancer Test Aces FDA Panel Review

WASHINGTON -- An FDA advisory committee unanimously affirmed the safety and efficacy of a DNA stool test for colorectal cancer screening.

Anti-PARP Tx Works in Advanced Ovarian Cancer

TAMPA, Fla. -- Advanced ovarian cancer treated with PARP inhibitor maintenance therapy had significant improvement in progression-free survival, extending beyond first progression, investigators reported.

Cancer Ascites Responds to Outpatient Tx

TAMPA, Fla. -- Outpatient treatment of malignant ascites with a monoclonal antibody proved safe and feasible and led to a survival benefit in gynecologic cancer patients who could receive chemotherapy, a small clinical study showed.

鈥�

104

鈥�